Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosis

  The pharmaceutical company Takeda announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis did not meet the first of two primary endpoints. Treatment with ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care…

Read more

ASH 2018 highlights in myeloma

Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018.

Read more
May

June 2026

July
MO
TU
WE
TH
FR
SA
SU
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
Events for 1st June
No Events
Events for 2nd June
No Events
Events for 3rd June
No Events
Events for 4th June
No Events
Events for 5th June
No Events
Events for 6th June
No Events
Events for 7th June
No Events
Events for 8th June
No Events
Events for 9th June
No Events
Events for 10th June
No Events
Events for 11th June
No Events
Events for 12th June
No Events
Events for 13th June
No Events
Events for 14th June
No Events
Events for 15th June
No Events
Events for 16th June
No Events
Events for 17th June
No Events
Events for 18th June
No Events
Events for 19th June
No Events
Events for 20th June
No Events
Events for 21st June
No Events
Events for 22nd June
No Events
Events for 23rd June
No Events
Events for 24th June
No Events
Events for 25th June
No Events
Events for 26th June
No Events
Events for 27th June
No Events
Events for 28th June
No Events
Events for 29th June
No Events
Events for 30th June
No Events